American Renal Associates Holdings, Inc (ARA): Price and Financial Metrics


American Renal Associates Holdings, Inc (ARA)

Today's Latest Price: $11.50 USD

0.01 (0.09%)

Updated Jan 22 7:00pm

Add ARA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 77 in Medical - Services

See all "A" rated Strong Buy stocks

ARA Stock Summary

  • American Renal Associates Holdings Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 1.46% of US listed stocks.
  • Price to trailing twelve month operating cash flow for ARA is currently 2.28, higher than merely 9.16% of US stocks with positive operating cash flow.
  • ARA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 1.49% of US stocks.
  • Stocks that are quantitatively similar to ARA, based on their financial statements, market capitalization, and price volatility, are CBB, WOW, DIN, MDCA, and WYND.
  • ARA's SEC filings can be seen here. And to visit American Renal Associates Holdings Inc's official web site, go to www.americanrenal.com.

ARA Stock Price Chart Interactive Chart >

Price chart for ARA

ARA Price/Volume Stats

Current price $11.50 52-week high $11.98
Prev. close $11.49 52-week low $5.57
Day low $11.48 Volume 146,800
Day high $11.52 Avg. volume 113,879
50-day MA $11.45 Dividend yield N/A
200-day MA $8.43 Market Cap 397.24M

American Renal Associates Holdings, Inc (ARA) Company Bio


American Renal Associates provides outpatient dialysis services in the United States. The company focuses on joint venture relationships with nephrologists. It offers services to hospitals that include dialysis patient discharge coordination; and acute inpatient dialysis services, such as inpatient hemodialysis, inpatient peritoneal dialysis, C.V.V.H., C.R.R.T., and apheresis. The company was founded in 1999 and is based in Beverly, Massachusetts.

ARA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$11.50$32.75 185%

We started the process of determining a valid price forecast for American Renal Associates Holdings Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that American Renal Associates Holdings Inc ranked in the 73th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 186.33% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for ARA, they are:

  • 35% of the company's capital comes from equity, which is greater than just 10.42% of stocks in our cash flow based forecasting set.
  • American Renal Associates Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
  • Relative to other stocks in its sector (Healthcare), American Renal Associates Holdings Inc has a reliance on debt greater than 91.98% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%179%
1%182%
2%185%
3%188%
4%191%
5%193%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ARA, try ENSG, CVS, FTLF, HAE, and ALXN.


ARA Latest News Stream


Event/Time News Detail
Loading, please wait...

ARA Latest Social Stream


Loading social stream, please wait...

View Full ARA Social Stream

Latest ARA News From Around the Web

Below are the latest news stories about American Renal Associates Holdings Inc that investors may wish to consider to help them evaluate ARA as an investment opportunity.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers – WTRE, ARA, RESI, NK

NEW YORK, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Watford Holdings Ltd. (NASDAQ: WTRE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Arch Capital Group Ltd. for $35.00 per share. If you are a Watford shareholder, click here to learn more about your rights and options.American Renal Associates Holdings, Inc. (NYSE: ARA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Innovative Renal Care, LLC, an affiliate of Nautic Partners, LLC, for $11.50 per share in cash. If you are an American Renal shareholder, click here to learn more about your...

Yahoo | December 30, 2020

Moore Kuehn Encourages CBMG, CLCT, TNAV, and ARA Investors to Contact Law Firm

NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: * Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) A proxy was recently filed with the SEC regarding the acquisition of Cellular Biomedicine by a consortium led by the company’s CEO Bizuo Liu. Under the proposed transaction, shareholders of Cellular Biomedicine will receive $19.75 for every share owned.   The investigation concerns whether Cellular Biomedicine’s board of di...

Yahoo | December 29, 2020

SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies - PRGX, STND, NK, EIDX, ARA

Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

Yahoo | December 29, 2020

STOCK ALERT: Monteverde & Associates Launches Legal Investigation for the Following Transaction

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:

Yahoo | December 26, 2020

Lifshitz Law Firm, P.C. Announces Investigation of ARA, BBIO, CIT, and EV

NEW YORK, NY / ACCESSWIRE / December 26, 2020 / Lifshitz Law Firm, P.

Yahoo | December 26, 2020

Read More 'ARA' Stories Here

ARA Price Returns

1-mo N/A
3-mo 0.26%
6-mo 83.41%
1-year 17.11%
3-year -38.93%
5-year N/A
YTD 0.44%
2020 10.41%
2019 -9.98%
2018 -33.79%
2017 -18.23%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8398 seconds.